Latham & Watkins advised Novo Holdings A/S (Novo) as the lead investor in its Series C investment into Freeline Therapeutics, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases. The Series C financing, raising US$120 million, was co-led by Novo, Eventide Asset Management and Wellington Management Company, with additional participation from Cowen Healthcare Investments, Acorn Bioventures and Ample Plus Fund.

Latham’s team was led by London corporate partner Robbie McLaren, with associates Emily Cridland and Georgina Scott.